Behavioural Neurology

Behavioural Neurology / 2006 / Article
Special Issue

Neuropharmacologic Approaches to Cognitive Rehabilitation

View this Special Issue

Open Access

Volume 17 |Article ID 315386 |

John M. Ringman, Jeffrey L. Cummings, "Current and Emerging Pharmacological Treatment Options for Dementia", Behavioural Neurology, vol. 17, Article ID 315386, 12 pages, 2006.

Current and Emerging Pharmacological Treatment Options for Dementia

Received26 Apr 2006
Accepted26 Apr 2006


Treatments for the symptomatic relief of Alzheimer’s disease are available but despite advances in our ability to treat persons with various forms of dementia, more effective treatments are needed. The cholinesterase inhibitors donepezil, rivastigmine, and galantamine have demonstrated efficacy in improving cognition and global status and to a lesser extent, behavioral abnormalities relative to placebo in patients with mild-to-moderate Alzheimer’s disease. Rivastigmine has been shown to benefit patients with dementia with Lewy Bodies and with dementia associated with Parkinson's disease. Donepezil and galantamine have also been shown to be mildly effective in dementia due to cerebral ischemia. Memantine has a distinct mechanism of action and is effective in moderate-to-severe AD. The benefits from these drugs, however, are limited and their long-term effectiveness has not been well-demonstrated. Their clinical utility is controversial. Many novel approaches that promise to provide more effective treatments are currently being pursued.

Copyright © 2006 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.